Dendreon Corp (DNDN)

0.06
0.00 6.02
NASDAQ : Health Care
Prev Close 0.06
Open 0.06
Day Low/High 0.06 / 0.06
52 Wk Low/High 0.04 / 3.46
Volume 1.37M
Avg Volume 5.11M
Exchange NASDAQ
Shares Outstanding 158.72M
Market Cap 20.16M
EPS -1.95
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Prostate Cancer Drug Reaction

Biotech Stock Mailbag: Prostate Cancer Drug Reaction

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Medivation Scores Big Prostate Cancer Drug Victory

Medivation Scores Big Prostate Cancer Drug Victory

Medivation's MDV3100 prolongs survival in late-stage study, sending shares soaring

Dendreon Stock Gaps Down On Today's Open (DNDN)

Dendreon Stock Gaps Down On Today's Open (DNDN)

Shares of Dendreon (Nasdaq:DNDN) were gapping down Thursday morning with an open price 27.5% lower than Wednesday's closing price. The stock closed at $10.46 yesterday and opened today's trading at $7.58.

Dendreon Risks Fading Into Irrelevancy

Dendreon Risks Fading Into Irrelevancy

Another bad quarter for the prostate cancer therapy Provenge raises risks that Dendreon will never become a sustainable business.

Today's Market Primer: Greece News Is the Driver

Today's Market Primer: Greece News Is the Driver

News from Europe, particularly Greece, is driving the market Thursday.

Dendreon CEO Discusses Q3 2011 Results - Earnings Call Transcript

Dendreon CEO Discusses Q3 2011 Results - Earnings Call Transcript

Dendreon CEO Discusses Q3 2011 Results - Earnings Call Transcript

Whole Foods, Dendreon: After-Hours Trading

Whole Foods, Dendreon: After-Hours Trading

Whole Foods Market and Dendreon were among the stocks seeing trading interest in Wednesday's after-hours action.

Dendreon Corp (DNDN): Today's Featured Health Care Loser

Dendreon Corp (DNDN): Today's Featured Health Care Loser

Dendreon was a leading decliner within the health care sector, falling 18 cents (-1.7%) to $10.46 on average volume.

Dendreon Reports Third Quarter 2011 Financial Results

Dendreon Reports Third Quarter 2011 Financial Results

Dendreon Corporation (NASDAQ:DNDN) today reported results for the third quarter ended September 30, 2011.

Exelixis Falls on FDA Prostate Cancer Trial Design Setback

Exelixis Falls on FDA Prostate Cancer Trial Design Setback

Exelixis faces a delay in reaching approval for its prostate cancer drug cabozantinib.

Dendreon Announces Webcast Presentations At Upcoming Conferences

Dendreon Announces Webcast Presentations At Upcoming Conferences

Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: Credit Suisse Healthcare Conference in Phoenix, Arizona on November 9, 2011 at 8:00 a.

Dendreon Begins Enrollment In Phase 2 Neu-ACT Trial For Second Active Cellular Immunotherapy Product Candidate, DN24-02

Dendreon Begins Enrollment In Phase 2 Neu-ACT Trial For Second Active Cellular Immunotherapy Product Candidate, DN24-02

Dendreon Corporation (Nasdaq: DNDN) today announced that the company has begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon’s investigational active cellular immunotherapy being evaluated for the ...

'Mad Money Lightning Round': Stick With Coca-Cola

'Mad Money Lightning Round': Stick With Coca-Cola

Cramer says it is a terrific stock with an attractive yield.

Analysts' Actions: MSFT, DNDN, RIMM, VZ, NFLX

Analysts' Actions: MSFT, DNDN, RIMM, VZ, NFLX

Here are today's top research calls.

Analyst Actions -- 10/13/2011

Here are today's top research calls.

Biotech Stock Mailbag: Somaxon, Transcept

Biotech Stock Mailbag: Somaxon, Transcept

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Dendreon To Host Conference Call On November 2, 2011 To Announce Third Quarter 2011 Financial Results

Dendreon To Host Conference Call On November 2, 2011 To Announce Third Quarter 2011 Financial Results

Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Wednesday, November 2, 2011 at 4:30 p.

Biotech's Burning Questions for Q3 Earnings

Biotech's Burning Questions for Q3 Earnings

Can Vertex maintain its momentum? Will Dendreon recover from the Provenge disaster? Biotech stocks face questions as earnings season begins.

Five Days Remain Before Deadline In Class-action Lawsuit Against Dendreon, Says Hagens Berman

Five Days Remain Before Deadline In Class-action Lawsuit Against Dendreon, Says Hagens Berman

Hagens Berman Sobol Shapiro LLP informs investors that less than one week remains before the deadline to move the court for lead plaintiff in a class-action lawsuit filed against Dendreon (NASDAQ: DNDN).

Dendreon Stock Hits New 52-Week Low (DNDN)

Dendreon Stock Hits New 52-Week Low (DNDN)

Dendreon (Nasdaq:DNDN) hit a new 52-week low Wednesday as it is currently trading at $9.14, below its previous 52-week low of $9.22 with 3.5 million shares traded as of two p.m. ET. Average volume has been 6.3 million shares over the past 30 days.

Bayer Drug Hailed as Prostate Cancer Game Changer

Bayer Drug Hailed as Prostate Cancer Game Changer

Bayer's Alpharadin could complicate efforts by Amgen and Exelixis to advance their own prostate cancer therapies.

Law Office Of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Dendreon Corporation

Law Office Of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Dendreon Corporation

Law Office of Brodsky & Smith, LLC announces a class action lawsuit in the U.

Catching the Wave: Parabolas Abound

Catching the Wave: Parabolas Abound

And the winner of the Granddaddy Parabolic Pattern Award is …

The 5 Dumbest Things on Wall Street: Sept. 16

The 5 Dumbest Things on Wall Street: Sept. 16

Here is this week's roundup of the dumbest actions on Wall Street.

Analysts' Actions: CIT, DNDN, NYT, PFE, RIMM

Analysts' Actions: CIT, DNDN, NYT, PFE, RIMM

Here's a look at today's top research calls.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

10 Stocks to Watch: VeriSign, Ulta Salon

10 Stocks to Watch: VeriSign, Ulta Salon

VeriSign shares are plunging in premarket trading Friday on news that the company's Chief Financial Officer Brian Robins had resigned.

Dendreon, Ulta Beauty: After-Hours Trading

Dendreon, Ulta Beauty: After-Hours Trading

Dendreon and Ulta Beauty were among the stocks seeing heavy trading interest in Thursday's after-hours action.

Dendreon Announces Company Restructuring And Provides Update On PROVENGE

Dendreon Announces Company Restructuring And Provides Update On PROVENGE

Dendreon Corporation (NASDAQ:DNDN) today announced restructuring plans, overall cost reductions, and an update on PROVENGE® (sipuleucel-T) sales.

Dendreon Readies Cost-Cutting Plan

Dendreon Readies Cost-Cutting Plan

In the wake of the Provenge blowup, Dendreon is expected to announce cost cuts, including layoffs, on a conference call Thursday afternoon.